$5.94
Value $315M
MPLT and MRK stock compared: price, dividend, valuation and results, from SEC filings.
$5.94
Value $315M
$133.72
Value $331B
MapLight Therapeutics (MPLT) has a market value of $315M and Merck & Company (MRK) $331B. Over the last year, with dividends, MPLT moved -59.3% and MRK +44.8%. Dividend yield: MPLT none, MRK 2.54%.
The main figures of both. A bar only shows which number is larger, not which is better.
Market value
MPLT$315M
MRK$331B
MRK is 1,048 times MPLT
Revenue, 12 months
MPLT–
MRK$67.4B
Net income, 12 months
MPLT-$252M
MRK$2.5B
Operating margin
MPLT–
MRK–
ROIC
MPLT-29.1%
MRK3.9%
33.0 points apart
P/E
MPLT–
MRK134.8
Dividend yield
MPLT0.0%
MRK2.5%
2.5 points apart
A fainter bar means a negative number. The 5-year return includes dividends.
Both start at 100 at the beginning of the period, so the lines show how much each changed. With dividends means each dividend buys more shares.
MPLT-59.3%
MRK+44.8%
| Period | MPLTWith dividends | MRKWith dividends |
|---|---|---|
| 1 year since November 19, 2025 | -59.3%Price -59.3% | +44.8%Price +40.7% |
Each cell: the total return with dividends, its yearly rate, and the price change alone. Before taxes and costs. Past returns do not predict future ones.
As on each company's page. A description, not a recommendation: no one figure says which is better.
MPLTMapLight TherapeuticsMRKMerck & Company
| Price | $5.94 | $133.72 |
|---|---|---|
| Market value | $315M | $331B |
| Enterprise value (EV) | $31M | $375B |
| P/E | – | 134.8 |
| P/E, 5-year median | – | 14.8 |
| P/B | 0.7 | 7.4 |
| EV/EBIT | – | 78.7 |
| Free cash flow yield | – | 4.5% |
| Revenue, 12 months | – | $67.4B |
|---|---|---|
| Net income, 12 months | -$252M | $2.5B |
| Free cash flow, 12 months | -$179M | $14.7B |
| Earnings per share, 12 months | $83.51 | $0.98 |
| Revenue growth, year on year | – | 1.3% |
| Revenue growth a year, past | – | +9.4%over 5 years |
| EPS growth a year, past | – | +21.2%over 5 years |
| Gross margin | – | 71.8% |
|---|---|---|
| Operating margin | – | – |
| Net margin | – | 3.6% |
| ROIC | -29.1% | 3.9% |
| ROE | -91.4% | 5.2% |
| Cash | $284M | $9.7B |
|---|---|---|
| Total debt | $1.7M | $53.8B |
| Net debt / EBITDA | – | 5.7 |
| Interest cover | – | 2.4× |
| Dividend yield | – | 2.5% |
|---|---|---|
| Dividend per share, 12 months | – | $3.40 |
| Dividend growth a year, past | – | +5.8%over 5 years |
| Buyback yield | – | 1.5% |
| Shareholder yield | – | 4.1% |
Last 12 months from the latest 10-Q and 10-K. Value, P/E and yields at today's price. A dash means the figure does not exist or did not pass our checks.
By market value, Merck & Company ($331B) is about 1,048.2 times MapLight Therapeutics ($315M), at today's prices.
Since November 19, 2025, MPLT's price moved -59.3% and MRK's +40.7%. With dividends: MPLT -59.3% (-59.3% a year), MRK +44.8% (+44.8% a year). Past returns do not predict future ones.
The dividend yield at today's price is none for MapLight Therapeutics and 2.54% for Merck & Company. Over the last twelve months they paid – and $3.40 per share.
The page does not answer that and does not suggest buying or selling. It puts the two companies' numbers side by side, from their SEC filings, for you to read and form your own view. The decision depends on your goals and situation.
With each of the two, and with the largest in its sector.
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
Descriptive data from SEC filings and market prices.